Sweden

Dela

Kontakt

  • AstraZeneca
    Karlebyhus, Astraallén 151 85 SÖDERTÄLJE
    08-553 260 00
    08-553 290 00
    http://www.astrazeneca.se
  • Jacob Lund

    Extern kommunikationsdirektör


    +46 8 - 553 26020
    +46 72 560 21 57
    http://www.astrazeneca.se
  • Lotta Sjösten

    Presskontakt


    + 46 8 553 271 10
    + 46 72 739 60 52
    http://www.astrazeneca.se
  • Petra Eurenius

    Director Corporate Communication - Nordic Marketing Company


    +46 8 552 51396
    +46 70 918 65 62
    http://www.astrazeneca.se
    • Välj datumintervall -

    Upptäckter som räddar liv – årets tema för Sommarforskarskolan

    En sommar fylld av spännande experiment kring upptäckter som räddar liv. Låter det kul?Måndag 31 juli öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på Göteborgs universitet. Det är elever från årskurs 8 till årskurs 1 i gymnasiet som har sökt sig till skolan eftersom de är intresserade av att lära sig mer om naturvetenskap och teknik. Alla elever från de här årskurserna är välkomna att söka och eleverna antas inte baserat på

    KYNTHEUM APPROVED IN THE EU FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cellsAstraZeneca and MedImmune, its global biologics research and development arm, today announced that its partner LEO Pharma has been granted full marketing authorisation in all 28 EU member countries plus Iceland, Liechtenstein and Norway for Kyntheum (brodalumab), a new biologic medicine developed for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1 Kyntheum is the first and only biologic that selectively

    Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer

    CHMP positive recommendation is based on Phase III data demonstrating a 20% reduction in risk of disease worsening or death over anastrozoleAstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of Faslodex (fulvestrant) for the treatment of hormone receptor-positive (HR+), locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-

    Upptäckter som räddar liv – årets tema för Sommarforskarskolan

    En sommar fylld av spännande experiment kring upptäckter som räddar liv. Låter det kul?Måndag 19 juni öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på KTH i Stockholm. Det är elever från årskurs 8 till årskurs 1 i gymnasiet som har sökt sig till skolan eftersom de är intresserade av att lära sig mer om naturvetenskap och teknik. Alla elever från de här årskurserna är välkomna att söka och eleverna antas inte baserat på

    Nordisk registerstudie på ADA: Behandling av typ 2-diabetes med SGLT-2-hämmare förknippas med en minskad risk för förtida död och hjärtsvikt

    Resultat från den nordiska delen av observationsstudien CVD-REAL, baserad på registerdata från bland annat Sverige under åren 2012-2015, presenterades vid den amerikanska diabeteskongressen, ADA, den 11 juni. Resultaten visar att behandling av typ 2-diabetes med SGLT2-hämmare i klinisk verklighet är associerad med en signifikant minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.– Detta är mycket intressanta resultat, säger Jan Eriksson, professor i diabetologi vid Uppsala

    AstraZeneca presents new data underpinning safety profile and Real-World CV outcomes of Farxiga at ADA 2017

    Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitorsAstraZeneca presented new data at the American Diabetes Association’s (ADA) 77th Scientific Sessions underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical trials1, as well as three new cardiovascular (CV) outcomes analyses

    AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions

    Updated safety data on risk-benefit profile of Farxiga (dapagliflozin), three new analyses from the landmark CVD-REAL study, including Farxiga vs DPP-4 inhibitors, and a late-breaking oral presentation reveal further CV evidence across a broad population of patients with type-2 diabetes Data from DURATION-7 and DURATION-8 evaluating efficacy and safety of Bydureon (exenatide extended-release) in combination with basal insulin and Farxiga, respectively More than 50 abstracts demonstrate commitment to Cardiovascular and Metabolic DiseasesAstraZeneca and its global biologics research and

    AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig

    AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca’s strategic focus. Grünenthal will pay AstraZeneca $200 million upon completion. AstraZeneca will also receive up to an additional $102 million in future milestone payments. Grünenthal will acquire the rights to Zomig in all markets outside Japan, including the US, where the rights were previously licensed to Impax Pharmaceuticals (

    Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer

    OlympiAD was the first positive Phase III trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer Lynparza tablets reduced risk of disease worsening or death by 42% The overall safety profile was consistent with previous trials of LynparzaAstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choice of a

    AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

    Lynparza’s potential in BRCA-mutated metastatic breast cancer to be highlighted in plenary presentation of Phase III OlympiAD trial Key trials show further evidence of Tagrisso efficacy in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (AURA3 trial) or leptomeningeal disease (BLOOM trial) New data demonstrate advances in Immuno-Oncology, including Imfinzi in non-small cell lung and bladder cancerAstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is

    Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk

    Based on a composite measure of major adverse CV events (MACE), Bydureon did not increase cardiovascular (CV) risk and showed a consistent safety profile Fewer CV events were observed in the Bydureon arm, however, the efficacy objective of reduction in CV risk did not reach statistical significanceAstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the effect of once-weekly Bydureon (exenatide extended-release) versus placebo, when added to usual type-2 diabetes care, on the risk of MACE,

    Phase III Zonda trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients

    Patients treated with benralizumab were more than four times as likely to reduce oral corticosteroid (OCS) dose than those on placebo Benralizumab also reduced overall exacerbation rates by 70% and exacerbations requiring emergency room visits or hospitalisations by 93% in patients with severe, uncontrolled eosinophilic asthma Trial results published simultaneously in New England Journal of MedicineResults from the Phase III ZONDA trial 

    AstraZeneca enters agreement with Recordati for Seloken in Europe

    Agreement expands the commercial potential of Seloken in European markets AstraZeneca to receive upfront payment, plus ongoing income for established heart medicinesAstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure. Recordati will

    Brodalumab receives positive CHMP opinion for the treatment of adult patients with moderate-to-severe plaque psoriasis

    AstraZeneca today announced that its partner LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the approval of brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Brodalumab is the first and only fully human monoclonal antibody that selectively targets the IL-17 receptor. By binding to the receptor, brodalumab effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are

    AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017

    Phase III ZONDA trial shows the potential of benralizumab to reduce or discontinue the use of oral corticosteroidsAstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017. The breadth and depth of science behind AstraZeneca’s growing respiratory portfolio and pipeline are reflected in the 59 accepted abstracts, including three oral presentations and 13 poster discussions, which will

    Imfinzi significantly reduces the risk of disease worsening or death in the phase III pacific trial for stage III unresectable lung cancer

    Imfinzi met a primary endpoint of statistically-significant and clinically-meaningful progression-free survival (PFS) in ‘all-comer’ patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer in a planned interim analysis Imfinzi is the first immuno-oncology medicine to show superior PFS in this setting Plans for regulatory submission under active discussion with authoritiesAstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-

    AstraZeneca provides update on STRATOS 1 phase III trial of tralokinumab in severe, uncontrolled asthma

    Tralokinumab did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate Second pivotal Phase III trial STRATOS 2 is ongoing with results expected in second half of 2017AstraZeneca and MedImmune, its global biologics research and development arm, today announced that tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, did not meet its primary endpoint of a significant reduction in the annual asthma exacerbation rate (AAER) in the overall population of severe, uncontrolled asthma patients, compared with placebo in STRATOS 1, the

    AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer

    Approval granted regardless of PD-L1 status, based on tumour response rate and duration of response Imfinzi is the cornerstone in an extensive Immuno-Oncology programme across multiple cancer types and stages of diseaseAstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-

    AstraZeneca PLC:s resultatrapport för första kvartalet 2017

    En positiv start med fortsatt nyhetsflöde kring vår forskningsportfölj i det som har potential att bli ett avgörande år för bolaget  Ekonomisk sammanfattning  +-------------------+---------+---------+-----------------------+| |MUSD  | Förändring i %  |+-------------------+---------+---------+-----------------------+| | |Utfall[1]|i fasta valutakurser[2]|+-------------------+---------+---------+-----------------------+|Totala intäkter  | 5 405 | (12)  | (10)  |+-------------------+---------

    Tagrisso receives full approval in the EU

    Full approval follows Tagrisso’s expedited Conditional Marketing Authorisation as first-in-class medicine for patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer Tagrisso is a potential new standard of care in 2nd line and subsequent therapy in this hard-to-treat form of lung cancer Approval is based on Phase III AURA3 data which demonstrate significant clinical superiority of Tagrisso over chemotherapy in EGFR T790M mutation-positive NSCLC patients, including those with CNS metastasesAstraZeneca today announced that the European

    Tagrisso (osimertinib) receives US FDA full approval

    Conversion from accelerated to full approval confirms the potential of Tagrisso to become standard of care in the US Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso as compared to chemotherapyAstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-

    AstraZeneca’s potential medicine for Neuromyelitis Optica Spectrum Disorder receives orphan designation in Europe

    AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency (EMA) has granted orphan designation to inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Developed by MedImmune, inebilizumab is currently in Phase IIb clinical development for NMOSD. NMOSD is a rare, life-threatening autoimmune disease of the central nervous system in which the body’s immune system attacks healthy cells, most commonly in the optic nerves and spinal cord, resulting in severe damage. NMOSD may

    AstraZeneca to share its robust early science in Oncology with the medical community at AACR 2017

    60 abstracts from early oncology portfolio including 7 oral presentations, across Tumour Drivers and Resistance, Immuno-Oncology, Antibody-Drug Conjugates and DNA Damage Response Potential new medicines targeting cancer cell-death mechanisms highlight potential of emerging Tumour Drivers and Resistance researchAstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company’s next wave of innovative oncology medicines, at the American Association for Cancer

    Det finns inga träffar som matchar nuvarande filter
    Det finns inga fler träffar som matchar nuvarande filter
    Tillbaka till sidans topp

    Prenumerera

    Multimedia